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Antisense (AS) transcripts are RNA molecules that are transcribed from the opposite
strand to sense (S) genes forming S/AS pairs. The most prominent configuration is
when a lncRNA is antisense to a protein coding gene. Increasing evidences prove that
antisense transcription may control sense gene expression acting at distinct regulatory
levels. However, its contribution to brain function and neurodegenerative diseases
remains unclear. We have recently identified AS Uchl1 as an antisense to the mouse
Ubiquitin carboxy-terminal hydrolase L1 (Uchl1) gene (AS Uchl1), the synthenic locus of
UCHL1/PARK5. This is mutated in rare cases of early-onset familial Parkinson’s Disease
(PD) and loss of UCHL1 activity has been reported in many neurodegenerative diseases.
Importantly, manipulation of UchL1 expression has been proposed as tool for therapeutic
intervention. AS Uchl1 induces UchL1 expression by increasing its translation. It is the
representative member of SINEUPs (SINEB2 sequence to UP-regulate translation), a
new functional class of natural antisense lncRNAs that activate translation of their sense
genes. Here we take advantage of FANTOM5 dataset to identify the transcription start
sites associated to S/AS pair at Uchl1 locus. We show that AS Uchl1 expression is
under the regulation of Nurr1, a major transcription factor involved in dopaminergic
cells’ differentiation and maintenance. Furthermore, AS Uch1 RNA levels are strongly
down-regulated in neurochemical models of PD in vitro and in vivo. This work positions
AS Uchl1 RNA as a component of Nurr1-dependent gene network and target of cellular
stress extending our understanding on the role of antisense transcription in the brain.
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Introduction
Large genomic projects such as ENCODE (Derrien et al., 2012) and FANTOM (Forrest et al.,
2014) have shown that the majority of the mammalian genome is transcribed, thus generating
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a previously underestimated complexity in gene regulatory net-
works. A vast repertory of different classes of transcripts includes
non-coding RNAs and RNAs of Transposable Elements (TEs),
such as LINE (long interspersed nuclear element) and SINEs
(short interspersed nuclear element) (Katayama et al., 2005;
Faulkner et al., 2009; Kapranov et al., 2010; Fort et al., 2014).
Long non-coding RNA (lncRNA) genes seem to represent the
majority of cellular transcriptional output. The FANTOMproject
has cataloged more than 30,000 putative lncRNA transcripts by
full length cDNA cloning (Katayama et al., 2005) while NON-
CODEv4 currently contain 46,475 lncRNA genes (Xie et al., 2014;
Quek et al., 2015).
Antisense (AS) transcripts are RNA molecules that are tran-
scribed from the opposite strand to sense (S) genes forming S/AS
pairs. These are estimated to include the large majority of pro-
tein encoding genes and about one third of lncRNAs (Chen et al.,
2004; Katayama et al., 2005; Engstrom et al., 2006; Derrien et al.,
2012). The most prominent class of S/AS pair is when a protein-
encoding gene presents a lncRNA on the opposite strand. In a
growing number of cases, AS lncRNAs have been proved to be
required for proper regulation of sense genes, carrying genetic
information acting at distinct regulatory levels (Yu et al., 2008;
Spigoni et al., 2010; Tripathi et al., 2010). Understanding their
mode of action may be also relevant for gene expression manip-
ulation in vivo since lncRNAs may become in the near future a
new class of RNA-based drugs for therapeutic intervention.
The contribution of AS lncRNAs to neurodegenerative dis-
eases is still unclear although some significant examples in
Alzheimer’s disease (AD) (Faghihi et al., 2008, 2010), spinocere-
bellar ataxia type 7 (Sopher et al., 2011) and Huntington’s disease
(Chung et al., 2011) may suggest they play a prominent role in
neuronal homeostasis and dysfunction.
Parkinson’s disease (PD) is a slowly progressive degenerative
disorder of the central nervous system (CNS) that is classically
defined in terms ofmotor symptoms. The neuropathological hall-
mark in post-mortem brains is the selective degeneration of spe-
cific subsets of mesencephalic dopaminergic (DA) cells and the
formation of cytoplasmic aggregates called Lewy bodies. The cur-
rent model of toxicity of DA neurons includes mitochondrial
dysfunction, oxidative stress and alterations in protein turnover.
This stems from the observation on post-mortem PD brains as
well as from the identification of genes associated to rare forms of
early-onset familial PD. Some of these features are recapitulated
in a neurochemical model of the disease that takes advantage of
the selective accumulation of toxic MPP+ species in DA neurons.
So far, relevant examples for lncRNAs antisense to genes
involved in PD have been restricted to a transcript associated to
PINK1/PARK6 locus (Scheele et al., 2007).
Recently, we have identified a lncRNA that is antisense to the
mouse Ubiquitin carboxy-terminal hydrolase L1 (Uchl1) gene
Abbreviations: Uchl1, Ubiquitin Carboxy-terminal Hydrolase L1; S, sense; AS,
antisense; hCAGE, Heliscope Cap Analysis of Gene Expression; TSS, transcrip-
tion start site; lncRNA, long non-coding RNA; PD, Parkinson’s disease; DA,
dopaminergic; TH, tyrosine hydroxylase; Vmat2, vescicular monoamine trans-
porter 2; MPP+, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1, 2, 3,
6-tetrahydropyridine.
(AS Uchl1), the synthenic locus of UCHL1/PARK5 (Carrieri
et al., 2012).
Uchl1 encodes for one of the most abundant proteins in
the brain. It acts as deubiquinating enzyme, ubiquitin ligase
or monoubiquitin stabilizer, thus regulating ubiquitin turnover
(Liu et al., 2002). Dysfunction in UCHL1 has been reported
in many neurodegenerative diseases. A missense mutation in
UCHL1/PARK5 has been associated to rare cases of early-onset
familial PD. Inactivating oxidative modifications of UchL1 pro-
tein have been reported in PD post-mortem brains where it corre-
lates with the formation of protein aggregates (Choi et al., 2004;
Barrachina et al., 2006; Gong et al., 2006). In this context sev-
eral evidences position UchL1 as a major regulator of α-synuclein
degradation and toxicity (Liu et al., 2009). Lack of hydrolase
activity has also been found in recessive cases of a childhood-
onset progressive neurodegeneration (Bilguvar et al., 2013). An
in-frame deletion in the Uchl1 gene, as observed in the gracile
axonal dystrophy mice, leads to axonal dystrophy and prema-
ture death (Saigoh et al., 1999). Reduced UCHL1 protein lev-
els were also found in sporadic AD brains. Recently, UCHL1
overexpression has been shown to accelerate lysosomal degra-
dation of APP, inhibit plaque formation and improve memory
deficits in AD transgenic model mice (Gong et al., 2006). These
data proves UchL1 activity is required for proper brain func-
tion. Furthermore, they suggest that increasing UCHL1 expres-
sion in vivo may be a safe and effective disease-modifying strat-
egy to treat neurodegenerative diseases. It is therefore impor-
tant dissecting all the molecular events involved in Uchl1 gene
regulation.
AS Uchl1 is a 5′ head to head, 1.2 kb long transcript that ini-
tiates within the second intron of Uchl1 and overlaps the first
73 nts of the sense mRNA including the AUG codon. The non-
overlapping part of the transcript also contains an embedded
repetitive sequence SINEB2 of the B3 subclass in the inverted
orientation. AS Uchl1 is expressed in mouse mesencephalic DA
neurons, the site of degeneration in PD. In physiological con-
ditions AS Uchl1 RNA is nuclear-enriched. Upon rapamycin, it
shuttles from the nucleus to the cytoplasm and specifically tar-
gets Uchl1 mRNA to heavy polysomes for translation (Carrieri
et al., 2012). AS Uchl1 is the representative member of SINEUPs
(SINEB2 sequence to UP-regulate translation), a new functional
class of natural antisense lncRNAs that activate translation of
their sense genes (Zucchelli et al., submitted).
Cap Analysis of Gene Expression (CAGE) is a technology
based on the generation of short sequence tags from the 5′
end of full-length cDNAs followed by high-throughput sequenc-
ing. When mapped to a reference genome, CAGE tags survey
transcription start site (TSS) activity of specific promoters and
measure expression levels on a massive scale (Gustincich et al.,
2003; Shiraki et al., 2003; Carninci et al., 2006). The FANTOM5
(Functional Annotation of Mammals 5) project has developed
a simplified CAGE protocol adapted to single-molecule HeliS-
cope sequencer (hCAGE) (Kanamori-Katayama et al., 2011) to
decrease PCR biases and improve depth of sequencing. hCAGE
technology was applied to a wide range of human and mouse
tissues providing an unprecedented dataset for promoter usage
analysis (Forrest et al., 2014).
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Here we take advantage of FANTOM5 dataset to map TSSs
and analyze the expression of the S/AS pair at the Uchl1 mouse
locus. This led to the identification in the AS Uchl1 promoter
region of a binding site for Nurr1, a transcription factor required
for DA cells differentiation. Chromatin immuno-precipitation
and quantitative RT-PCR proved that AS Uchl1 expression is
under the control of Nurr1 activity. Finally, we show that tran-
scription of S/AS Uchl1 RNA is regulated in neurochemical
models of PD in vitro and in vivo.
Materials and Methods
Cell Lines
Murine dopaminergic MN9D cells with doxyciclin- inducible
induction of Nurr1 transcription factor (MN9D Nurr1 Tet-ON
stable cells, or iMN9D cells) were maintained in culture as previ-
ously described (Hermanson et al., 2003). Nurr1 expression was
obtained by culture with 2.5µg/ml doxycycline for 12 h or longer,
as required. For in vitro neurochemicalmodel of PD, iMN9D cells
were treated with 100µMMPP+ for 16 h.
ChIP Assay
Chromatin immunoprecipitation (ChIP) was performed with
magnetic beads (Dynabeads, Invitrogen) following the protocol
as described (Schmidt et al., 2009). For each ChIP, one conflu-
ent 100mm plate of iMN9D cell was treated with doxycicline
2.5µg/ml. Nurr1 expression upon doxycicline treatment was fol-
lowed by western blot. 1µg of ChIP-grade anti-Nurr1 antibody
was used (sc-990 X). Rabbit IgG were used as negative control
(Cell signaling #2729).
qPCR was performed with primers for DNA binding regions
of indicated targets and distal primers were designed for an
unrelated region 6000 bps upstream the AS Uchl TSS:
VMAT NBRE F: 5′-ATTGTGCTAACATTTATTCCAGAG-3′
VMAT NBRE R: 5′-AGGGCTTCCTACGTGACC-3′
OCN NBRE F: 5′-CCACAACACGCATCCTTT-3′
OCN NBRE R: GGACTTGTCTGTTCTGCA-3′
AS Uchl1 NBRE F: 5′ CTTCCCATACAGCTTAGTTCC-3′
AS Uchl1 NBRE R 5′-TTGCGTCTCTGCCAGATG-3′
Distal F 5′-TCATCCAGCCACAAGGTCAGAG-3′
Distal R 5′- CCAGCAGGCACACTGTTGAAC-3′
Enrichment of chromatin binding was calculated relative to
total input, as described previously (Guccione et al., 2006).
RNA Isolation, Reverse Transcription and
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from iMN9D cells or dissected mouse
ventral midbrain using TRIZOL reagent (Invitrogen) and follow-
ing manufacturer’s instructions. RNA was treated with DNAse
I (Ambion) before use. Single strand cDNA was prepared from
1µg of purified RNA using the iSCRIPT™ cDNA Synthesis Kit
(Bio-Rad) according to manufacturer’s instructions. qRT-PCR
reaction was performed using SYBR-Green PCR Master Mix
(Applied Biosystem) and an iCycler IQ Real time PCR System
(Bio-Rad). Oligonucleotide sequences of primers used in this
study were previously described (Carrieri et al., 2012). qRT-PCR
for Nur77 was performed with the following primers:
Nur77-FWD CCTCATCACTGATCGACACG
Nur77-REV CCTCCAACTTGAGGCAAAAG
MPTP Treatment
Mice used in this study were treated according to the NIH guide-
lines for Care and Use of Laboratory Animals. MPTP use and
safety precautions were as described previously (Jackson-Lewis
and Przedborski, 2007). All animal experiments were performed
in accordance with European guidelines for animal care and fol-
lowing SISSA Ethical Committee permissions. Mice were housed
and bred in SISSA non-SPF animal facility, with 12 h dark/light
cycles and controlled temperature and humidity. Mice had ad
libitum access to food and water.
Eight-week-old, male, TH-GFP mice (Sawamoto et al., 2001)
were subjected to a sub-acute MPTP regimen (Jackson-Lewis and
Przedborski, 2007). Animals received one intra-peritoneal injec-
tion ofMPTP-HCl (free base suspended in saline; Sigma-Aldrich)
at 20mg kg−1 dose every 2 h for a total of four doses over an 8 h
period (Tatton and Kish, 1997; Miller et al., 2004; Gibrat et al.,
2009). Injection of saline solution was used in control mice. Ani-
mals were sacrificed 2 days or 7 days after last injection, as these
time-points were previously associated to variations in Uchl1 and
Nurr1 expression (Miller et al., 2004; Gibrat et al., 2009). 300
DA neurons were purified by laser capture microdissection as
described previously (Biagioli et al., 2009; Carrieri et al., 2012)
and used for RNA extraction and qRT-PCR.
Bioinformatic Analysis
Analysis of FANTOM5 collection of mouse libraries was per-
formed using the Zenbu browser genomic tool (Severin et al.,
2014) and publicly available FANTOM5 datasets (http://fantom.
gsc.riken.jp/5/) (Forrest et al., 2014). A specific script was
designed to extract expression values from graphical tables in
Zenbu Genome Browser and convert into Excel spreadsheet for
further analysis (Paolo Vatta, unpublished). Expression values for
S/AS Uchl1 were calculated for a window of about ±800 base
pairs around main TSS. Selection of brain-specific libraries was
done by manual annotation.
For co-expression analysis, average expression values were cal-
culated for S/AS transcripts in libraries that express both and
divergence from average was considered.
For ChIP experiments, identification of NGFI-B binding ele-
ments was performed with the Genomatrix program (http://
genomatrix.de) and the TRANSFAC database (Knuppel et al.,
1994). The mouse AS Uchl1 genome region from kb −3000 to
+1000 was the reference sequence. Trascriptional binding factor
motifs were chosen on the basis of core similarity (score 1.0) and
matrix similarity (above 0.80).
Results
Evidence of AS Uchl1 Transcription in Mouse
FANTOM5 Collection of Cell Lines, Primary Cells
and Tissues
We first interrogated FANTOM5 expression data for almost
400 mouse samples, covering cell lines, primary cells and
tissues. These dataset are build from hCAGE libraries and
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are based on sequencing cDNA copies of the 5′ ends of
mRNAs, of which the integrity is inferred by the presence
of their cap. These sequences—referred to as tags—are suffi-
ciently long to be aligned in most cases at a single location
in the genome. The first position of this alignment identi-
fies a base pair where transcription is initiated defining a TSS.
The number of times a given tag is represented in a library
gives an estimate of the expression level of the corresponding
transcript.
Since antisense lncRNAs are typically expressed at much
lower level than overlapping protein-coding transcripts (Der-
rien et al., 2012; Forrest et al., 2014) (Zucchelli et al., FAN-
TOM5 satellite, submitted), we used FANTOM5 mouse datasets
in which no expression cutoff was applied to detect values as
low as 1 count per library. Tags were positively scored if map-
ping to a region of about 800 bp around the main TSS of Uchl1
(Figures 1A, 3). Expression was measured as Tag Per Million
(TPM).
While sensemRNA is expressed in almost all analyzed samples
(90% of libraries), only 40% of them score positive for antisense
transcription proving AS Uchl1 expression is relatively restricted
(Figure 1B). Sense mRNA is present at higher levels as com-
pared to its antisense (Figure 1C). Both transcripts are highly
expressed in the brain (Figure 1D). In particular AS Uchl1 RNA
is present in the cortex, striatum and hippocampus (TPM 3.2-
2.2) although its highest level is measured in testis (TPM 5.38).
Within FANTOM5 dataset, about 50 libraries were prepared
from blood-derived primary cells (B cells, T cells, macrophages,
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FIGURE 1 | General features of S/AS Uchl1 expression in mouse
FANTOM5 datasets. (A) Schematic view of S/AS Uchl1 pair with 5′
head-to-head divergent anatomy. (B) FANTOM5 collection of 367
libraries from mouse cell lines, primary cells and tissues were
interrogated for expression of Uchl1 gene in sense and antisense
orientation. Pie-chart representation of S/AS expression in FANTOM5
dataset. (C) Distribution of S/AS levels in mouse libraries. Transcript
levels are expressed as tag per millions (TPM). (D) Higher levels of S
and AS Uchl1 are enriched in the brain. Data were obtained from
N = 144 FANTOM5 libraries that express both transcripts. Low and high
levels of S and AS Uchl1 were defined based on average expression
values for each transcript.
Frontiers in Cellular Neuroscience | www.frontiersin.org 4 April 2015 | Volume 9 | Article 114
Carrieri et al. Antisense Uchl1 in dopaminergic neurons
lymphoid and myeloid progenitor cells, megakaryocyte precur-
sor cells) and tissues related to immune system (spleen and
thymus). Very low expression is detected for AS Uchl1 (0.2
TPM) in only one/two of the replicas from naïve CD4 T cells,
c-Kit+ stem cells and common myeloid progenitors (data not
shown).
To assess whether transcription in opposite orientation is co-
regulated, we analyzed FANTOM5 libraries containing tags for
both RNAs (N = 144 libraries). Since Spearman Correlation
analysis could not be applied, we calculated average TPM levels
for each transcript and set this value to 1. We then normal-
ized expression values in all libraries to the reference and mon-
itored variation from the average. We found that the majority
of libraries (N = 122) displays concordant variation of S/AS
transcription from the average, with both positive and negative
co-regulation. When expression of S/AS pair is not co-regulated
(N = 22), variation from average values goes in both directions
and is almost equally present in non-brain (N = 9) and brain
(N = 13) libraries.
Since FANTOM5 collection comprises a set of brain regions
for which neonatal and adult tissues are available, we monitored
S/AS transcription in brain development. As previously found,
sense and antisense levels are positively co-regulated with val-
ues in neonatal tissues often higher than in adult samples of the
same area (Figure 2A). High levels of AS Uchl1 RNA are detected
in neonatal corpus striatum, cortex, hippocampus and medulla
oblungata.
As each brain region is composed of several cellular types of
neuronal and non-neuronal origin, we monitored S/AS expres-
sion in primary brain cells as well as in neurospheres. Again,
we found that the expression of S and AS Uchl1 RNAs is co-
regulated. Both transcripts are highly expressed in neurons as
compared to non-neuronal cells, with those from the Striatum,
the Substantia Nigra and Raphe being the highest (Figure 2B).
Interestingly, values in neurospheres prepared from cells isolated
from different compartments show reduced quantities as com-
pared to primary neurons. Non-neuronal cells have very low
(Schwann cells) to undetectable (astrocytes) levels of Uchl1 S/AS
pair.
Therefore, expression of S and AS Uchl1 is co-regulated in the
developing and adult brain.
Analysis of TSS Usage in Mouse Uchl1 Gene
Locus
To monitor promoter usage in mouse Uchl1 locus, we visual-
ized single TSSs using the FANTOM5 Zenbu Genome Browser,
a publicly available web resource tool (http://fantom.gsc.riken.
jp/zenbu/) (Severin et al., 2014). To identify promoters across
the genome the FANTOM5 consortium has developed a method
based on tags proximity and signal decomposition (Forrest et al.,
2014). To enrich for TSSs, 3 tags/library thresholds were applied
and promoter subsets were defined and classified according to
their robustness. For our analysis, we interrogated all hCAGE
libraries pooled together and then we focused our attention on
those with stronger evidences of TSS usages, as testis, cortex and
primary neurons of the Substantia Nigra. As shown in Figure 3,
three different TSSs can be identified using decomposition-based
identification method and referred to as p1, p2 and p3, from 5′
to 3′ according to the sense of transcription. These drive expres-
sion of alternative variants of AS Uchl1 RNA. TSS usage is under
tissue- and cell-specific regulation, as documented by different
TPM values in the selected libraries. Interestingly, expression of
AS Uchl1 reference sequence is validated by TSSs in testis and
Substantia Nigra neurons, but this promoter does not pass the
bioinformatics cutoffs. p2 and p1 are the most used promoters,
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FIGURE 2 | S/AS Uchl1 are regulated during development and enriched
in neurons. (A) Heat map graphical representation of S/AS expression in
neonatal and adult tissues from brain and other organs. Expression values of
S/AS transcripts in cortex were set to 1. (B) Heat map of S/AS Uchl1 in
brain-derived primary cells and in neurospheres. Values in cortical neurons
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FIGURE 3 | Analysis of TSS usage in mouse S/AS Uchl1. Zenbu
Genome Browser view of mouse Uchl1 locus. Sense transcripts are in
green, antisense in purple. hCAGE data are presented for those libraries
(testis, cortex and Substantia Nigra neurons), where antisense
expression is highest. Purple arrows highlight antisense TSSs identified
by FANTOM5 data analysis (p1, p2, and p3, 5′ to 3′ orientation relative
to AS Uchl1) and by RACE experiments in MN9D cells. TSS supporting
the expression of RefSeq AS Uchl1 transcript in testis and Substantia
Nigra is also indicated. Promoters identified with FANTOM5
decomposition-based peak identification method are shown at the
bottom (original promoter nomenclature is given). Black arrow indicated
an alternative transcript variant of sense Uchl1. The 5′ end of AS Uchl1
cDNA cloned from mouse dopaminergic MN9D cell line is shown
(Carrieri et al., 2012).
giving rise to transcript variants with a longer 5′ end. It is of
note that 5′ end of AS Uchl1, as identified by RACE in murine
dopaminergic MN9D cell line (Carrieri et al., 2012), is posi-
tioned upstream to p1 (Figure 3). Finally, an additional site of
transcription initiation can be observed at the 3′ end of AS
Uchl1 (p3), thus identifying a yet not-annotated variant with a
shorter first exon. p3 seems to be under control of a bidirectional
promoter.
The protein-coding Uchl1 mRNA starts almost exclusively
from an internal portion of the 5′ UTR of the annotated tran-
script. It is shorter and independently validated by mm9 mRNAs
(Figure 3). Interestingly, an alternative promoter for Uchl1 is also
located around exon 3 and drives expression in testis (Figure 3,
black arrow). This TSS identifies an annotated but yet unchar-
acterized transcript (AK170728), which potentially encodes for
a shorter Uchl1 protein, lacking a canonical initiation methio-
nine. Whether such protein is indeed functional remains to be
established.
Nurr1 Activity Regulates AS Uchl1 Expression
The genomic region −1500/+1000 around the annotated AS
Uchl1 TSS was then scanned for the presence of Transcription
Factor Binding Sites (TFBSs). A NGFI-B element was identified
in position −1230/−1222 to the AS Uchl1 TSS as defined by
RACE (Figure 4A). This TFBS is the target of the Nurr subfamily
of nuclear receptors including Nurr1, a key dopaminergic tran-
scription factor required for late-dopaminergic differentiation
and crucial for the expression of several dopaminergic-specific
genes like VMAT2, AADC, DAT, and TH (Castro et al., 2001).
To study the role of this transcription factor in AS Uchl1 RNA
transcription, we took advantage of mouse dopaminergic MN9D
cell line overexpressing Nurr1 under a doxycicline inducible pro-
moter (iMN9D cells) (Hermanson et al., 2003). In steady-state
conditions, levels of Nurr1 protein are almost undetectable and
AS Uchl1 is expressed at low level. Upon drug treatment, Nurr1
expression increases and Nurr1 target genes are induced (Her-
manson et al., 2003). As a consequence, differentiation of DA
neurons occurs (Figure 4B).
We then carried out chromatin immunoprecipitation (ChIP)
experiments. iMN9D cells were treated with doxocycline for
12 h to achieve high levels of Nurr1 protein. Chromatin-protein
complexes were then immunoprecipitated with anti-Nurr1 or
control (IgG) antibodies and bound genomic DNA was quan-
tified by qPCR using primers for Nurr1 response elements in
AS Uchl1, Osteocalcin and Vescicular Monoamine Transporter
2 gene promoters. PCR reactions generated only the expected
specific amplicon, as detected by gel electrophoresis and melting
curve analysis (data not shown). As shown in Figure 4C, Nurr1
binding was significantly enriched relative to IgG control in AS
Uchl1 promoter region.
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 April 2015 | Volume 9 | Article 114
Carrieri et al. Antisense Uchl1 in dopaminergic neurons
ACAGCTTAGTTCCGGTCAGGTCAAGGATGCCTCTAGAACACCTG
1.20
1.00
0.80
0.60
0.20
0.40
Vmat2 Ocn AS Uchl1
Distal 
Primers
%
 o
f 
in
p
u
t
Rabbit igG
Nurr1 Ab
5
4
3
2
1
*
**
*
0 16 24 48 96 hours
N
o
rm
a
liz
e
d
 f
o
ld
 e
x
p
re
s
s
io
n
 
(∆
∆C
t)
Uchl1
TH
AS Uchl1
A
Uchl1
AS Uchl1
67,067,000 67,068,000 67,069,000
p1
p2p3
 NGFI-B/Nur77 RE
-1230-1222
mm9 chr5
B
C
FIGURE 4 | AS Uchl1 is primary target of Nurr1 transcription factor.
(A) Scheme of Nurr1 TFBS upstream AS Uchl1. Genomic coordinates (top),
S/AS Uchl1 transcript anatomy (middle), and AS Uchl1 promoters (bottom)
are shown. NGFI-B/Nur77 response element (NBRE) is indicated in gray and
positioned to its genomic coordinates and relative to AS Uchl1 TSSs.
(B) AS Uchl1 expression is up-regulated during differentiation. iMN9D cells
were treated with doxocyclin at the indicated times. AS and S Uchl1
expression were monitored by qRT-PCR. Expression of TH was used as
positive control for dopaminergic differentiation. *p < 0.05; **p < 0.01.
(C) Immunoprecipitation of Nurr1-bound chromatin was performed from
murine dopaminergic iMN9D cells treated with doxocyclin for 12 h to induce
Nurr1 expression. Rabbit IgGs and distal primers targeting an unrelated
region were used as controls. Chromatin immunoprecipitation of VMAT2 and
OCN promoter regions were included as positive controls of Nurr1 binding.
Nurr1 induction led to a rapid up-regulation of AS Uchl1
RNA levels starting from 12 h, with kinetics comparable to
the one observed for VMAT2, a well-known primary target
of Nurr1. Within 48 h, both AS Uchl1 and VMAT2 mRNAs
reached their peak of induction, while decreasing at later time
points. Under these conditions, Nur77, another member of
nuclear receptors family targeting NGFI-B motif, is undetectable
(Supplementary Figure 1).
Interestingly, we found that transcription of sense protein-
coding Uchl1 mRNA was poorly linked to Nurr1 activity, as the
kinetics and strength of Uchl1mRNA up-regulation was different
from that of VMAT2 and AS Uchl1 (Figure 4B).
Expression of Mouse AS Uchl1 is
Down-Regulated in Neurochemical Models of PD
In Vitro and In Vivo
We then investigated the behavior of Uchl1 S/AS pair in neuro-
chemical models of PD. First, we analyzed the effects of intox-
ication on S/AS Uchl1 levels in vitro. When iMN9D cells were
exposed to 100µM 1-methyl-4-phenylpyridinium (MPP+) for
16 h, we observed that expression of both transcripts was altered
and a statistically significant co-reduction could be measured.
While AS Uchl1 RNA was reduced to only 25% of its physiologi-
cal level, the impact on Uchl1 mRNA was less pronounced, with
only 30% reduction (Figure 5A).
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To test whether S/AS transcription is regulated during
DA neuron intoxication in vivo, we injected mice with
1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), fol-
lowing a sub-acute protocol (Jackson-Lewis and Przedborski,
2007). To uncouple transcriptional control of S/AS expres-
sion from down-regulation due to cell loss, we resolved to
laser capture microdissection of fluorescently labeled DA neu-
rons from TH-GFP transgenic mice to purify equal num-
bers of cells from untreated and treated animals. Under
these conditions, surviving DA neurons showed an almost
complete loss of AS Uchl1 transcript but a modest down-
regulation of Uchl1 mRNA (Figure 5B) recapitulating what
we had observed in vitro in iMN9D cells treated with
MPP+.
Altogether, these data show that AS Uchl1 is a component
of the Nurr1-dependent dopaminergic gene network and is
down-regulated in neurotoxicity.
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FIGURE 5 | S/AS Uchl1 pair is co-downregulated in PD neurochemical
models in vitro and in vivo. (A) qRT-PCR of S and AS Uchl1 transcript levels
in iMN9D cells treated with 100µM MPP+ for 16 h. *p < 0.05; **p < 0.01.
(B) TH-GFP mice were treated with MPTP or saline control (ctrl). Animals were
sacrificed at the indicated times. RNA was extracted from LCM-purified DA
neurons and used for qRT-PCR. Data indicate mean ± s.d., n = 8. *p < 0.05;
**p < 0.01.
Discussion
One of the key features of genomes’ organization is that the large
majority of genes share their genomic region with another gene
on the opposite filament forming S/AS pair (Carninci et al., 2005;
Derrien et al., 2012). Massive antisense transcription seems to
be a common feature of cells ranging from bacteria to human
(Katayama et al., 2005; Van Dijk et al., 2011). Despite some
provocative examples we poorly understand how each locus
decides between repressive and activating responses to antisense
transcription suggesting we are still missing the basic princi-
ples of regulatory choices and molecular switches. This is par-
ticularly relevant when we consider that lncRNAs and antisense
transcription may be exploited in RNA therapeutics.
The S/AS pair at the Uchl1 locus is organized according to the
configuration where a protein-encoding gene presents a lncRNA
on the opposite strand, overlapping “head-to-head” at their 5′
ends. AS Uchl1 is the representative member of SINEUPs, a new
functional class of natural and synthetic antisense lncRNAs that
activate translation. Their activity depends on the combination
of two RNA elements: the overlapping region is indicated as the
Binding Doman (BD) while the embedded inverted SINEB2 ele-
ment is the Effector Domain (ED). The ED is required for the
increase of translation of the protein-coding sense mRNA and
the BD is targeting the activity to the sense transcript.
UchL1 is one of the most abundant proteins in the brain
where it is expressed in selected neuronal cell types. We have
previously shown that in iMND9 cells, the very same cell line
used in this study, its mRNA is associated to light polysomes
for basal translation. In these conditions AS Uchl1 is mainly
restricted to the nucleus where it exerts an unknown function.
S/AS transcripts are also co-expressed in mesencephalic DA cells
in vivo where they retain their differential subcellular localiza-
tion. Upon inhibition of mTOR activity by rapamycin, AS Uchl1
shuttles to the citoplasm where it facilitates Uchl1 mRNA loading
to heavy polisomes for a more efficient translation and increase
in cellular UchL1 protein levels. Both rapamycin treatment and
Uchl1 over-expression are considered neuroprotective suggesting
that antisense-mediated translation may be part of a pro-survival
cellular response to stress.
A first step toward a better understanding of antisense tran-
scription consists in studying how its expression is regulated.
Increasing information is accumulating over the role of DNA
methylation and selected TFs such as Sox2, Oct4, and Nanog
on the control of long intergenic non-coding RNAs (lincRNAs)
(Guttman et al., 2009) whereas very little is known about the
transcriptional regulation of the lncRNAs component of S/AS
pairs. Recent genome-wide studies on human cell lines evidence
epigenetic regulation of AS lncRNAs expression, with accumula-
tion of histone marks and RNA polymerase II occupancy (Con-
ley and Jordan, 2012). Interestingly, TSSs in antisense orienta-
tion frequently associate with transposable elements, suggesting
that repetitive sequences might contribute to regulation of AS
transcription (Conley et al., 2008; Kapusta et al., 2013). Few gene-
specific examples exist in which transcriptional control of a nat-
ural AS transcript has been investigated. This is the case, for
example, of S/AS Msx1 in which the promoter region of AS RNA
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contains binding sites forMsx1 transcription factor, thus generat-
ing an auto-regulatory loop of S/AS regulation (Petit et al., 2009;
Babajko et al., 2011). In prostate cancer cell line, the expression
of CTBP1-AS is regulated by binding of androgen receptor at the
5′ of its TSS. Upon androgen-dependent activation of CTBP1-
AS, the overlapping protein-coding gene (CTBP1) is repressed
(Takayama et al., 2013).
Here we find that almost all the FANTOM5 libraries present
evidences of Uchl1 transcription while AS Uchl1 is expressed
only in 40% of them. This data raise the question about how
UchL1 protein synthesis is regulated in physiological conditions
and upon stress in the absence of antisense transcription. It
will be interesting to assess whether Uchl1 mRNA is normally
associated to heavy polisomes and whether mTOR inhibition or
stress are able to increase UchL1 protein levels according to an
antisense–independent mechanism. This is particularly relevant
considering that UchL1 is target of oxidative stress inactivation
and is down-regulated in post-mortem brains of neurodegen-
erative diseases. In summary these data may raise the inter-
esting possibility of differences in the anti-stress control and
function of Uchl1 expression dependent on the presence of AS
Uchl1 RNA.
We did not find any example of AS Uchl1 expression in the
absence of Uchl1. Therefore, it is not surprising that when both
S/AS pair transcripts are present they show a concordant pattern
of expression. The highest levels of AS Uchl1 have been found in
Substantia Nigra, striatum and diencephalon. This analysis con-
firmsASUchl1 is present in selected regions of the brain as shown
in Carrieri et al. (2012).
Interestingly, neonatal neurons express larger quantity of
AS Uchl1 RNA than adult tissues. This is in line with recent
genome-wide and gene-specific studies that indicate spatiotem-
poral regulation of AS lncRNAs expression during cerebral cor-
ticogenesis (Ling et al., 2011; Lipovich et al., 2013) and aging
(Pardo et al., 2013) (Francescatto et al., FANTOM5 satellite,
submitted).
Even when AS Uchl1 is highly expressed, its levels are lower
than Uchl1 mRNA. However, we know that AS Uchl1 is able
to increase the amount of UchL1 protein through its activity
on Uchl1 mRNA. The quantity of UchL1 protein in vivo is the
sum of several molecular events ranging from transcription to
mRNA localization, rate of protein synthesis and degradation. It
is unclear what is the life cycle of a single Uchl1 mRNA from
transcription to its association to ribosomes or stress granules
and P bodies. Therefore, it remains crucial to determine which
fraction of total cellular Uchl1 mRNA is associated to light poli-
somes in physiological conditions and how much is available for
RNA-RNA interaction and association to heavy polisomes in an
antisense-dependent fashion under stress.
By decomposition-based identification method three differ-
ent promoters can be defined while evidences for additional
TSSs are shown. While p1 and p2 extend the overlapping region
at genomic level respect to the annotated sequence of refer-
ence, a previously reported cDNA clone obtained with RACE
starts 5′ to p1. p3 identifies a non-overlapping transcript proba-
bly involved in a bidirectional promoter. Interestingly, a poten-
tial internal alternative TSS for Uchl1 is evidenced in testis
and Substantia Nigra suggesting the possibility of a N-terminal
truncated protein.
At 1230 nt from the TSS of AS Uchl1 identified with RACE,
a DNA binding site for Nurr1 has been bioinformatically dis-
covered and experimentally validated. Nurr1 is a member of
the nuclear receptor superfamily, whose expression is crucial
for DA neurons differentiation and maintenance in the adult
(Zetterstrom et al., 1997; Saucedo-Cardenas et al., 1998; Kad-
khodaei et al., 2009, 2013). Importantly, reduced quantities of
Nurr1 in adult mice increase DA cells vulnerability to neurotoxic
insults (Le et al., 1999). In humans, Nurr1 polymorphisms have
been associated to sporadic PD (Xu et al., 2002; Grimes et al.,
2006) and reduced Nurr1 levels have been measured in periph-
eral blood and brain of PD patients (Chu et al., 2002; Liu et al.,
2012). In summary, Nurr1 controls the major transcriptional
axis for differentiation of DA neurons and maintenance of their
integrity.
This work strongly suggests that AS Uchl1 is a component of
Nurr1-dependent transcriptional network. This functional inter-
action adds a new layer to the complexity of circuitry that may
contribute to DA cells’ homeostasis.
We then prove that neurochemical intoxication of DA cells
down-regulates S/AS expression in vitro and in vivo with a kinet-
ics that impact more strongly ASUchl1 than its overlapping sense
mRNA. This is different from the consequences of pharmaco-
logical inhibition of mTOR where no effects on transcription
were observed (Carrieri et al., 2012). Further studies are needed
to understand whether survival or apoptotic outocomes of dif-
ferent treatments reside, at least in part, on the ability to reg-
ulate antisense RNAs at transcriptional or post-transcriptional
levels.
In summary, antisense transcription imposes an additional
level of regulatory networks to control the activity of protein-
coding genes. Determining the repertory of transcription fac-
tors controlling the expression of AS RNAs under physiological
and pathological conditions will further contribute to our under-
standing on the biological functions of AS lncRNAs in health
and disease. Finally, since increasing evidences suggest Uchl1
over-expression could be beneficial in neurodegenerative dis-
eases, the use of AS Uchl1 as RNA-based drug may represent a
new therapeutic strategy.
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Supplementary Figure 1 | Nur77 expression in iMN9D cells. iMN9D cells
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positive control for Nurr1-mediated activation. Data were analyzed using the
2−1Ct method. Data indicate mean ± SD. Nurr1 expression was verified by
western blotting.
References
Babajko, S., Meary, F., Petit, S., Fernandes, I., and Berdal, A. (2011). Transcrip-
tional regulation of MSX1 natural antisense transcript. Cells Tissues Organs
(Print). 194, 151–155. doi: 10.1159/000324466
Barrachina, M., Castano, E., Dalfo, E., Maes, T., Buesa, C., and Ferrer, I. (2006).
Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with
Lewy bodies. Neurobiol. Dis. 22, 265–273. doi: 10.1016/j.nbd.2005.11.005
Biagioli, M., Pinto, M., Cesselli, D., Zaninello, M., Lazarevic, D., Roncaglia, P.,
et al. (2009). Unexpected expression of alpha- and beta-globin in mesen-
cephalic dopaminergic neurons and glial cells. Proc. Natl. Acad. Sci. U.S.A. 106,
15454–15459. doi: 10.1073/pnas.0813216106
Bilguvar, K., Tyagi, N. K., Ozkara, C., Tuysuz, B., Bakircioglu, M., Choi, M., et al.
(2013). Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1
leads to early-onset progressive neurodegeneration. Proc. Natl. Acad. Sci. U.S.A.
110, 3489–3494. doi: 10.1073/pnas.1222732110
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M. C., Maeda, N., et al.
(2005). The transcriptional landscape of the mammalian genome. Science 309,
1559–1563. doi: 10.1126/science.1112014
Carninci, P., Sandelin, A., Lenhard, B., Katayama, S., Shimokawa, K., Ponjavic, J.,
et al. (2006). Genome-wide analysis of mammalian promoter architecture and
evolution. Nat. Genet. 38, 626–635. doi: 10.1038/ng1789
Carrieri, C., Cimatti, L., Biagioli, M., Beugnet, A., Zucchelli, S., Fedele, S., et al.
(2012). Long non-coding antisense RNA controls Uchl1 translation through
an embedded SINEB2 repeat. Nature 491, 454–457. doi: 10.1038/nature
11508
Castro, D. S., Hermanson, E., Joseph, B., Wallen, A., Aarnisalo, P., Heller, A.,
et al. (2001). Induction of cell cycle arrest and morphological differentiation by
Nurr1 and retinoids in dopamineMN9D cells. J. Biol. Chem. 276, 43277–43284.
doi: 10.1074/jbc.M107013200
Chen, J., Sun, M., Kent, W. J., Huang, X., Xie, H., Wang, W., et al. (2004). Over
20% of human transcripts might form sense-antisense pairs. Nucleic Acids Res.
32, 4812–4820. doi: 10.1093/nar/gkh818
Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L. S., et al.
(2004). Oxidative modifications and down-regulation of ubiquitin carboxyl-
terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s
diseases. J. Biol. Chem. 279, 13256–13264. doi: 10.1074/jbc.M314124200
Chu, Y., Kompoliti, K., Cochran, E. J., Mufson, E. J., and Kordower, J. H. (2002).
Age-related decreases in Nurr1 immunoreactivity in the human substantia
nigra. J. Comp. Neurol. 450, 203–214. doi: 10.1002/cne.10261
Chung, D. W., Rudnicki, D. D., Yu, L., and Margolis, R. L. (2011). A natural
antisense transcript at the Huntington’s disease repeat locus regulates HTT
expression. Hum. Mol. Genet. 20, 3467–3477. doi: 10.1093/hmg/ddr263
Conley, A. B., and Jordan, I. K. (2012). Epigenetic regulation of human
cis-natural antisense transcripts. Nucleic Acids Res. 40, 1438–1445. doi:
10.1093/nar/gkr1010
Conley, A. B., Miller, W. J., and Jordan, I. K. (2008). Human cis natural antisense
transcripts initiated by transposable elements. Trends Genet. 24, 53–56. doi:
10.1016/j.tig.2007.11.008
Derrien, T., Johnson, R., Bussotti, G., Tanzer, A., Djebali, S., Tilgner, H., et al.
(2012). The GENCODE v7 catalog of human long noncoding RNAs: analysis
of their gene structure, evolution, and expression. Genome Res. 22, 1775–1789.
doi: 10.1101/gr.132159.111
Engstrom, P. G., Suzuki, H., Ninomiya, N., Akalin, A., Sessa, L., Lavorgna, G., et al.
(2006). Complex Loci in human and mouse genomes. PLoS Genet. 2:e47. doi:
10.1371/journal.pgen.0020047
Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan,
T. E., et al. (2008). Expression of a noncoding RNA is elevated in Alzheimer’s
disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med.
14, 723–730. doi: 10.1038/nm1784
Faghihi, M. A., Zhang, M., Huang, J., Modarresi, F., Van Der Brug, M. P., Nalls, M.
A., et al. (2010). Evidence for natural antisense transcript-mediated inhibition
of microRNA function. Genome Biol. 11:R56. doi: 10.1186/gb-2010-11-5-r56
Faulkner, G. J., Kimura, Y., Daub, C. O., Wani, S., Plessy, C., Irvine, K. M., et al.
(2009). The regulated retrotransposon transcriptome of mammalian cells. Nat.
Genet. 41, 563–571. doi: 10.1038/ng.368
Forrest, A. R., Kawaji, H., Rehli, M., Baillie, J. K., De Hoon, M. J., Haberle, V., et al.
(2014). A promoter-level mammalian expression atlas. Nature 507, 462–470.
doi: 10.1038/nature13182
Fort, A., Hashimoto, K., Yamada, D., Salimullah, M., Keya, C. A., Saxena, A., et al.
(2014). Deep transcriptome profiling of mammalian stem cells supports a reg-
ulatory role for retrotransposons in pluripotency maintenance. Nat. Genet. 46,
558–566. doi: 10.1038/ng.2965
Gibrat, C., Saint-Pierre, M., Bousquet, M., Levesque, D., Rouillard, C., and Cic-
chetti, F. (2009). Differences between subacute and chronic MPTP mice
models: investigation of dopaminergic neuronal degeneration and alpha-
synuclein inclusions. J. Neurochem. 109, 1469–1482. doi: 10.1111/j.1471-
4159.2009.06072.x
Gong, B., Cao, Z., Zheng, P., Vitolo, O. V., Liu, S., Staniszewski, A., et al.
(2006). Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases
in synaptic function and contextual memory. Cell 126, 775–788. doi:
10.1016/j.cell.2006.06.046
Grimes, D. A., Han, F., Panisset, M., Racacho, L., Xiao, F., Zou, R., et al. (2006).
Translated mutation in the Nurr1 gene as a cause for Parkinson’s disease.Mov.
Disord. 21, 906–909. doi: 10.1002/mds.20820
Guccione, E., Martinato, F., Finocchiaro, G., Luzi, L., Tizzoni, L., Dall’ Olio, V.,
et al. (2006). Myc-binding-site recognition in the human genome is determined
by chromatin context. Nat. Cell Biol. 8, 764–770. doi: 10.1038/ncb1434
Gustincich, S., Batalov, S., Beisel, K. W., Bono, H., Carninci, P., Fletcher, C. F.,
et al. (2003). Analysis of the mouse transcriptome for genes involved in the
function of the nervous system. Genome Res. 13, 1395–1401. doi: 10.1101/gr.11
35303
Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., et al.
(2009). Chromatin signature reveals over a thousand highly conserved large
non-coding RNAs in mammals. Nature 458, 223–227. doi: 10.1038/nature
07672
Hermanson, E., Joseph, B., Castro, D., Lindqvist, E., Aarnisalo, P., Wallen, A., et al.
(2003). Nurr1 regulates dopamine synthesis and storage in MN9D dopamine
cells. Exp. Cell Res. 288, 324–334. doi: 10.1016/S0014-4827(03)00216-7
Jackson-Lewis, V., and Przedborski, S. (2007). Protocol for theMPTPmousemodel
of Parkinson’s disease. Nat. Protoc. 2, 141–151. doi: 10.1038/nprot.2006.342
Kadkhodaei, B., Alvarsson, A., Schintu, N., Ramskold, D., Volakakis, N., Jood-
mardi, E., et al. (2013). Transcription factor Nurr1 maintains fiber integrity and
nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc.
Natl. Acad. Sci. U.S.A. 110, 2360–2365. doi: 10.1073/pnas.1221077110
Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta,
M., et al. (2009). Nurr1 is required for maintenance of maturing and
adult midbrain dopamine neurons. J. Neurosci. 29, 15923–15932. doi:
10.1523/JNEUROSCI.3910-09.2009
Kanamori-Katayama, M., Itoh, M., Kawaji, H., Lassmann, T., Katayama, S.,
Kojima, M., et al. (2011). Unamplified cap analysis of gene expres-
sion on a single-molecule sequencer. Genome Res. 21, 1150–1159. doi:
10.1101/gr.115469.110
Kapranov, P., Ozsolak, F., Kim, S. W., Foissac, S., Lipson, D., Hart, C., et al.
(2010). New class of gene-termini-associated human RNAs suggests a novel
RNA copying mechanism. Nature 466, 642–646. doi: 10.1038/nature09190
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 April 2015 | Volume 9 | Article 114
Carrieri et al. Antisense Uchl1 in dopaminergic neurons
Kapusta, A., Kronenberg, Z., Lynch, V. J., Zhuo, X., Ramsay, L., Bourque, G.,
et al. (2013). Transposable elements are major contributors to the origin, diver-
sification, and regulation of vertebrate long noncoding RNAs. PLoS Genet.
9:e1003470. doi: 10.1371/journal.pgen.1003470
Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakanishi, M., Nakamura, M.,
et al. (2005). Antisense transcription in the mammalian transcriptome. Science
309, 1564–1566. doi: 10.1126/science.1112009
Knuppel, R., Dietze, P., Lehnberg, W., Frech, K., and Wingender, E. (1994).
TRANSFAC retrieval program: a network model database of eukaryotic tran-
scription regulating sequences and proteins. J. Comput. Biol. 1, 191–198. doi:
10.1089/cmb.1994.1.191
Le, W., Conneely, O. M., He, Y., Jankovic, J., and Appel, S. H. (1999). Reduced
Nurr1 expression increases the vulnerability of mesencephalic dopamine neu-
rons to MPTP-induced injury. J. Neurochem. 73, 2218–2221.
Ling, K. H., Hewitt, C. A., Beissbarth, T., Hyde, L., Cheah, P. S., Smyth, G. K., et al.
(2011). Spatiotemporal regulation of multiple overlapping sense and novel nat-
ural antisense transcripts at the Nrgn and Camk2n1 gene loci during mouse
cerebral corticogenesis. Cereb. Cortex 21, 683–697. doi: 10.1093/cercor/bhq141
Lipovich, L., Tarca, A. L., Cai, J., Jia, H., Chugani, H. T., Sterner, K. N., et al.
(2013). Developmental changes in the transcriptome of human cerebral cor-
tex tissue: long noncoding RNA transcripts. Cereb. Cortex 24, 1451–1459. doi:
10.1093/cercor/bhs414
Liu, H., Wei, L., Tao, Q., Deng, H., Ming, M., Xu, P., et al. (2012). Decreased
NURR1 and PITX3 gene expression in Chinese patients with Parkinson’s
disease. Eur. J. Neurol. 19, 870–875. doi: 10.1111/j.1468-1331.2011.03644.x
Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z., and Lansbury, P. T. Jr. (2002). The
UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-
synuclein degradation and Parkinson’s disease susceptibility. Cell 111, 209–218.
doi: 10.1016/S0092-8674(02)01012-7
Liu, Z., Meray, R. K., Grammatopoulos, T. N., Fredenburg, R. A., Cook-
son, M. R., Liu, Y., et al. (2009). Membrane-associated farnesylated UCH-
L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for
Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 106, 4635–4640. doi:
10.1073/pnas.0806474106
Miller, R. M., Callahan, L. M., Casaceli, C., Chen, L., Kiser, G. L., Chui, B.,
et al. (2004). Dysregulation of gene expression in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J. Neurosci. 24,
7445–7454. doi: 10.1523/JNEUROSCI.4204-03.2004
Pardo, L. M., Rizzu, P., Francescatto, M., Vitezic, M., Leday, G. G., Sanchez,
J. S., et al. (2013). Regional differences in gene expression and pro-
moter usage in aged human brains. Neurobiol. Aging 34, 1825–1836. doi:
10.1016/j.neurobiolaging.2013.01.005
Petit, S., Meary, F., Pibouin, L., Jeanny, J. C., Fernandes, I., Poliard, A., et al. (2009).
Autoregulatory loop of Msx1 expression involving its antisense transcripts.
J. Cell. Physiol. 220, 303–310. doi: 10.1002/jcp.21762
Quek, X. C., Thomson, D. W., Maag, J. L., Bartonicek, N., Signal, B., Clark, M. B.,
et al. (2015). lncRNAdb v2.0: expanding the reference database for functional
long noncoding RNAs. Nucleic Acids Res. 43(Database issue), D168–D173. doi:
10.1093/nar/gku988
Saigoh, K., Wang, Y. L., Suh, J. G., Yamanishi, T., Sakai, Y., Kiyosawa, H., et al.
(1999). Intragenic deletion in the gene encoding ubiquitin carboxy-terminal
hydrolase in gad mice. Nat. Genet. 23, 47–51. doi: 10.1038/12647
Saucedo-Cardenas, O., Quintana-Hau, J. D., Le, W. D., Smidt, M. P., Cox, J. J., De
Mayo, F., et al. (1998). Nurr1 is essential for the induction of the dopamin-
ergic phenotype and the survival of ventral mesencephalic late dopamin-
ergic precursor neurons. Proc. Natl. Acad. Sci. U.S.A. 95, 4013–4018. doi:
10.1073/pnas.95.7.4013
Sawamoto, K., Nakao, N., Kobayashi, K., Matsushita, N., Takahashi, H., Kakishita,
K., et al. (2001). Visualization, direct isolation, and transplantation of mid-
brain dopaminergic neurons. Proc. Natl. Acad. Sci. U.S.A. 98, 6423–6428. doi:
10.1073/pnas.111152398
Scheele, C., Petrovic, N., Faghihi,M. A., Lassmann, T., Fredriksson, K., Rooyackers,
O., et al. (2007). The human PINK1 locus is regulated in vivo by a non-coding
natural antisense RNA during modulation of mitochondrial function. BMC
Genomics 8:74. doi: 10.1186/1471-2164-8-74
Schmidt, D.,Wilson,M. D., Spyrou, C., Brown, G. D., Hadfield, J., andOdom, D. T.
(2009). ChIP-seq: using high-throughput sequencing to discover protein-DNA
interactions.Methods 48, 240–248. doi: 10.1016/j.ymeth.2009.03.001
Severin, J., Lizio, M., Harshbarger, J., Kawaji, H., Daub, C. O., Hayashizaki, Y., et al.
(2014). Interactive visualization and analysis of large-scale sequencing datasets
using ZENBU. Nat. Biotechnol. 32, 217–219. doi: 10.1038/nbt.2840
Shiraki, T., Kondo, S., Katayama, S., Waki, K., Kasukawa, T., Kawaji, H., et al.
(2003). Cap analysis gene expression for high-throughput analysis of transcrip-
tional starting point and identification of promoter usage. Proc. Natl. Acad. Sci.
U.S.A. 100, 15776–15781. doi: 10.1073/pnas.2136655100
Sopher, B. L., Ladd, P. D., Pineda, V. V., Libby, R. T., Sunkin, S. M., Hurley, J. B.,
et al. (2011). CTCF regulates ataxin-7 expression through promotion of a con-
vergently transcribed, antisense noncoding RNA. Neuron 70, 1071–1084. doi:
10.1016/j.neuron.2011.05.027
Spigoni, G., Gedressi, C., and Mallamaci, A. (2010). Regulation of Emx2 expres-
sion by antisense transcripts in murine cortico-cerebral precursors. PLoS ONE
5:e8658. doi: 10.1371/journal.pone.0008658
Takayama, K., Horie-Inoue, K., Katayama, S., Suzuki, T., Tsutsumi, S., Ikeda, K.,
et al. (2013). Androgen-responsive long noncoding RNA CTBP1-AS promotes
prostate cancer. EMBO J. 32, 1665–1680. doi: 10.1038/emboj.2013.99
Tatton, N. A., and Kish, S. J. (1997). In situ detection of apoptotic nuclei in the
substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-
treated mice using terminal deoxynucleotidyl transferase labelling and acri-
dine orange staining. Neuroscience 77, 1037–1048. doi: 10.1016/S0306-
4522(96)00545-3
Tripathi, V., Ellis, J. D., Shen, Z., Song, D. Y., Pan, Q., Watt, A. T., et al. (2010).
The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing
by modulating SR splicing factor phosphorylation. Mol. Cell 39, 925–938. doi:
10.1016/j.molcel.2010.08.011
Van Dijk, E. L., Chen, C. L., D’aubenton-Carafa, Y., Gourvennec, S., Kwapisz, M.,
Roche, V., et al. (2011). XUTs are a class of Xrn1-sensitive antisense regulatory
non-coding RNA in yeast. Nature 475, 114–117. doi: 10.1038/nature10118
Xie, C., Yuan, J., Li, H., Li, M., Zhao, G., Bu, D., et al. (2014). NONCODEv4: explor-
ing the world of long non-coding RNA genes.Nucleic Acids Res. 42, D98–D103.
doi: 10.1093/nar/gkt1222
Xu, P. Y., Liang, R., Jankovic, J., Hunter, C., Zeng, Y. X., Ashizawa, T., et al. (2002).
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene
with Parkinson’s disease. Neurology 58, 881–884. doi: 10.1212/WNL.58.6.881
Yu, W., Gius, D., Onyango, P., Muldoon-Jacobs, K., Karp, J., Feinberg, A. P., et al.
(2008). Epigenetic silencing of tumour suppressor gene p15 by its antisense
RNA. Nature 451, 202–206. doi: 10.1038/nature06468
Zetterstrom, R. H., Solomin, L., Jansson, L., Hoffer, B. J., Olson, L., and Perlmann,
T. (1997). Dopamine neuron agenesis in Nurr1-deficient mice. Science 276,
248–250. doi: 10.1126/science.276.5310.248
Conflict of Interest Statement: SG, PC, CC, AF, and SZ are named inventors in
patent issued in the US Patent and Trademark Office on SINEUPs and licensed to
TransSINE Technologies. SG and PC are co-founders of PARKscreen, an Italian
SME aimed to use and develop therapeutic SINEUPs.
Copyright © 2015 Carrieri, Forrest, Santoro, Persichetti, Carninci, Zucchelli and
Gustincich. This is an open-access article distributed under the terms of the Cre-
ative Commons Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 April 2015 | Volume 9 | Article 114
